title: Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia.
abstract: Clonidine has been proposed to differentiate multiple system atrophy (MSA) from idiopathic Parkinson's disease (IPD), as it does not increase growth hormone (GH) release in MSA. We studied GH release in response to clonidine in 7 IPD patients, 6 MSA patients, 4 patients affected by idiopathic late-onset cerebellar ataxia (ILOCA) and 8 healthy controls. In addition, we investigated the effects of GH releasing hormone plus arginine (GHRH-Arg) on GH release in the same patients. Both clonidine and GHRH-Arg raised serum GH levels in all groups examined. Clonidine failed to differentiate MSA from IPD and ILOCA. GHRH-Arg showed a lower increase of serum GH in MSA patients than in other groups, even if such difference was not statistically significant. We suggest that stimulation of GH release with GHRH-Arg rather than clonidine could differentiate MSA from IPD and ILOCA, but this hypothesis would need to be confirmed by further investigations.
authors.affiliation: Department of Neurological Sciences, University Federico II, Naples, Italy.
authors.forename: M T
authors.initials: MT
authors.lastname: Pellecchia
authors.forename: E
authors.initials: E
authors.lastname: Salvatore
authors.forename: R
authors.initials: R
authors.lastname: Pivonello
authors.forename: A
authors.initials: A
authors.lastname: Faggiano
authors.forename: P
authors.initials: P
authors.lastname: Barone
authors.forename: G
authors.initials: G
authors.lastname: De Michele
authors.forename: A M
authors.initials: AM
authors.lastname: Colao
authors.forename: A
authors.initials: A
authors.lastname: Filla
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000009:adverse effects; D001120:Arginine / Q000008:administration & dosage / Q000009:adverse effects; D003000:Clonidine / Q000008:administration & dosage / Q000009:adverse effects; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D013006:Growth Hormone / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D019578:Multiple System Atrophy / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology; D010300:Parkinson Disease / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology; D013132:Spinocerebellar Degenerations / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology
chemical_list: D000316:Adrenergic alpha-Agonists; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine; D003000:Clonidine